Sign up


Match Document Document Title
US20140072624 UNIT DOSE FORM FOR ORAL ADMINISTRATION  
Formulations and unit dose forms of TH-302 and other hypoxia activated prodrugs suitable for oral administration are useful for treating cancer.
US20130095177 METHOD OF PREPARING AN ORAL DOSAGE FORM COMPRISING FINGOLIMOD  
The present invention relates to a method of preparing an intermediate containing fingolimod, a method of preparing granules containing fingolimod, a method of preparing an oral dosage form...
US20110059170 METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS  
Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the...
US20140065210 PROTEIN STABILIZED PROBIOTICS AND PERSONAL CARE PRODUCTS  
The present invention relates to a personal care product comprising a protein matrix wherein said protein matrix comprises at least one protein, at least one probiotic and a carrier fluid. The...
US20120148671 GASTRIC RETAINED GABAPENTIN DOSAGE FORM  
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
US20120207828 LARGE DOSE RIBAVIRIN FORMULATIONS  
The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg...
US20120189693 ORAL DOSAGE FORMS  
Aspects of the present invention are directed to oral dosage forms comprising a compressed microtablet, wherein said microtablet has a major dimension that is between about 0.25 mm and about 1.0 mm...
US20110091545 Direct Injection moldable and rapidly disintegrating tablet matrix  
The present invention relates to a novel directly compressible matrix for the production of tablets which disintegrate rapidly in the presence of moisture, in particular in the mouth.
US20130101670 FORMULATIONS COMPRISING COATED FINE PARTICLES  
[OBJECT] To provide an intraorally rapidly disintegrating tablet comprising 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxyli c acid as an active ingredient, which is a formulation that...
US20120171286 METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF STATIN-INDUCED MYOPATHY  
Disclosed are methods for treating or preventing a statin-mediated myopathy in a subject via administration of a therapeutically effective amount of a geranylgeranylation activator. Further...
US20140287042 Oral Tablet Formulation Consisting Of Fixed Combination Of Rosuvastatin And Ezetimibe For Treatment Of Hyperlipidemia And Cardiovascular Diseases  
The present invention is an orally consumed fixed combination formulation of both rosuvastatin and ezetimibe in one tablet that is expected to have the same Area Under Curve as two active...
US20130280325 COMPRESSED SOLID DOSAGE FORMS  
This invention relates to compressed solid oral dosage form able to contain a high load of active pharmaceutical ingredient, showing a controlled release profile, and consisting of individual...
US20140141078 Dissolvable TableT  
A dissolvable tablet is disclosed. The tablet includes a front side, an obverse side and a thickness between the front side and the obverse side. The front side and obverse side have a variation of...
US20140112985 METHOD OF PREVENTION AND TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION  
This invention relates to prophylactic and/or therapeutic application of microorganism species that are, for example, administered orally as delayed release formulation designed to release its...
US20140065215 CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS OF NITAZOXANIDE  
Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is...
US20140294952 DISSOLVABLE MEDICATION ADMISISTRATION BAG AND METHOD OF USING THE SAME  
A dissolvable medication administration bag for the safe and effective crushing and administration of medication to patients who have difficulty swallowing pills is disclosed herein. In some...
US20130142870 NERAMEXANE MULTIPLE UNIT DOSAGE FORM  
Unit comprising neramexane, a pharmaceutically acceptable salt, solvate, conjugate, prodrug, polymorphic form, isomer, or derivative thereof; and a release-controlling excipient; wherein said unit...
US20130224294 DRY PROCESSING OF ATAZANAVIR  
The invention relates to dry processes for producing oral dosage forms, more specifically tablets, comprising atazanavir and adhesion enhancers. The invention further relates to compacted...
US20140141053 MICROLAYER COEXTRUSION TO CREATE A TIME-RELEASE DRUG SUBSTANCE DELIVERY PRODUCT  
The present invention relates to medical devices containing time-release drug substance, and more particularly, to medical tubing, catheters, stents, cables (including fiber optic cables), pills,...
US20110217372 Fast dissolving oral tablets and method for production thereof  
Provided is a fast dissolving oral tablet, and a method for the production thereof, including the steps of: compressing a mixture of active ingredients, pharmaceutically acceptable additives, and...
US20080175905 ESTROGEN/SERM AND ESTROGEN/PROGESTIN BI-LAYER TABLETS  
The present invention is directed to bi-layer tablets comprising at least one estrogen in a first layer and a therapeutic agent in a second layer, and processes for their preparation.
US20140105971 MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA IN HYPERCALCEMIC PATIENTS AND IMPROVED CALCIUM-CONTAINING COMPOSITIONS FOR THE TREATMENT OF HYPERKALEMIA  
The present invention relates to novel calcium-containing microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at...
US20140294953 Abuse-Resistant Formulations  
The disclosure relates to a sustained-release oral dosage form for once-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydromorphone. The...
US20110091544 Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting  
Small tablets for use in procedural sedation, anxiolysis and analgesia comprising the combination sufentanil and triazolam administered via the oral transmucosal route and methods for using the...
US20120135069 NANONIZED TESTOSTERON FORMULATIONS FOR IMPROVED BIOAVAILABILITY  
Nanonized formulations of testosterone esters, especially testosterone undecanoate, and of testosterone are prepared which show an enhanced oral bioavailability compared to the existing oral...
US20130230576 MICROLAYER COEXTRUSION TO CREATE A TIME-RELEASE DRUG  
Medical devices containing time release drug substance are disclosed, including medical tubing, catheters, stents, cables (including fiber optic cables), pills, capsules, sheaths, threads, clamps,...
US20120231075 ABUSE-RESISTANT OPIOID DOSAGE FORM  
We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.
US20110020444 ABUSE-RESISTANT OPIOID DOSAGE FORM  
We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.
US20130011474 MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE  
The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing...
US20110064805 Porous cellulose aggregate and molding composition thereof  
A porous cellulose aggregate characterized by having a secondary aggregate structure resulting from aggregation of primary cellulose particles, having a pore volume within a particle of 0.265 to...
US20110038927 CONTROLLED RELEASE HYDROCODONE FORMULATIONS  
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof,...
US20120034301 TABLET AND PESTLE THEREFOR  
A tablet which comprises solid particles, especially magnesium oxide particles as the main component and has excellent shape retentivity with extremely low susceptibility to wearing and chipping....
US20130011476 STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN  
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface...
US20130011475 STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN  
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface...
US20120156292 STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN  
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface...
US20120156291 STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN  
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface...
US20120164218 SOLID DOSAGE FORMS OF VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE AND METHOD OF MAKING THE SAME  
Monolayer, bilayer and trilayer solid dosage forms of a combination of valsartan, amlodipine and hydrochlorothiazide are made.
US20120177733 SOLID DOSAGE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD OF MAKING THE SAME  
Monolayer and bilayer solid dosage forms of a combination of valsartan and amlodipine are made.
US20100303906 SOLID DOSAGE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD OF MAKING SAME  
Monolayer and bilayer solid dosage forms of a combination of valsartan and amlodipine are made.
US20120183606 DRUG DELIVERY SYSTEM COMPRISING POLYOXAZOLINE AND A BIOACTIVE AGENT  
The invention relates to drug delivery systems comprising a water-soluble polymer matrix and a bioactive agent entrained therein, said water soluble polymer matrix containing at least 50 wt. % of...
US20130156821 SOLID GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF  
In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about...
US20120195965 SOLID DOSAGE FORM COMPRISING A FIBRATE  
The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to...
US20110311622 METHOD FOR ADDING SENSORY CONDITIONING CUES IN A PHARMACOTHERAPEUTIC REGIMEN  
A method for administering pharmaceutical agents to a subject is provided. The method includes the steps of: a) providing a course of treatment for a subject, which course includes periodically...
US20120009257 Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren  
The invention provides a pharmaceutical oral fixed dose combination of aliskiren and valsartan. Aliskiren is shown to slow the dissolution rate of valsartan and the resultant undesirable gelling of...
US20110268798 ORALLY DISNTEGRATING TABLETS FOR THE TREATMENT OF PAIN  
An orally disintegrating tablet comprising acetylsalicylic acid, acetaminophen and caffeine and one or more pharmaceutically acceptable excipients.
US20120135075 DOSAGE FORM  
The present invention provides a dosage form, particularly a tamper resistant dosage form, comprising: melt-extruded particulates comprising a drug; and a matrix; wherein said melt-extruded...
US20060188566 Nanoparticulate formulations of docetaxel and analogues thereof  
Described are nanoparticulate docetaxel or analogue thereof compositions. The compositions, which comprise a nanoparticulate docetaxel or analogue thereof and at least one surface stabilizer, can...
US20130039981 Quick Dissolving, Long Acting Zinc Therapeutic Formulations  
The present invention comprises a quick dissolving, long acting zinc therapeutic cold formulation containing high levels of an active compound encapsulated within bioadhesive/muco-adhesive polymers...
US20140105976 PHARMACEUTICAL FORMULATIONS OF PILOCARPINE  
Disclosed herein are pharmaceutical compositions comprising at least one minitablet, where the minitablet comprises a core, comprising pilocarpine, or a pharmaceutically acceptable salt thereof;...
US20130011479 DOUBLE-LAYER PHARMACEUTICAL FORMULATIONS CONTAINING OPIOID AGONISTS AND ANTAGONISTS  
Immediate-release formulations are described, consisting of double-layer tablets wherein one layers contains an opioid agonist and the other an opioid antagonist.